Synergy CHC Corp. (SNYR) Key Statistics & Metrics

Synergy CHC Corp. (SNYR) has an ST Score of 46.6 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate SNYR a Buy, with a price target of $7.50 (+8187.3% vs the current price). Our ST Score grades it C+ (46.6/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B, Profitability C+, Financial Strength B-, Momentum D-, Growth C+, Forecast A.

Synergy CHC Corp. (SNYR) earns a valuation grade of B, measured against Medical - Distribution peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Synergy CHC Corp. (SNYR) earns a growth grade of C+, measured against Medical - Distribution peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Synergy CHC Corp. (SNYR) earns a profitability grade of C+, measured against Medical - Distribution peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Synergy CHC Corp. (SNYR) earns a financial strength grade of B-, measured against Medical - Distribution peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Synergy CHC Corp. (SNYR) is $7.50 from 2 analysts, which is +8187.3% versus the recent price of $0.09.

Synergy CHC Corp. (SNYR) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.